Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic) (2016 - 2026)

Gyre Therapeutics has reported EPS (Basic) over the past 16 years, most recently at -$0.02 for Q4 2025.

  • Quarterly EPS (Basic) fell 1619.09% to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.05 through Dec 2025, down 64.29% year-over-year, with the annual reading at $0.06 for FY2025, 57.14% down from the prior year.
  • EPS (Basic) was -$0.02 for Q4 2025 at Gyre Therapeutics, down from $0.04 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.64 in Q2 2022 and troughed at -$1.54 in Q4 2023.
  • The 5-year median for EPS (Basic) is $0.0 (2024), against an average of -$0.22.
  • Year-over-year, EPS (Basic) soared 356.25% in 2022 and then plummeted 1619.09% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.64 in 2021, then crashed by 100.0% to -$1.28 in 2022, then fell by 20.31% to -$1.54 in 2023, then surged by 99.92% to -$0.0 in 2024, then plummeted by 1619.09% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EPS (Basic) are -$0.02 (Q4 2025), $0.04 (Q3 2025), and $0.0 (Q2 2025).